[go: up one dir, main page]

PE20081374A1 - Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina - Google Patents

Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina

Info

Publication number
PE20081374A1
PE20081374A1 PE2007001239A PE2007001239A PE20081374A1 PE 20081374 A1 PE20081374 A1 PE 20081374A1 PE 2007001239 A PE2007001239 A PE 2007001239A PE 2007001239 A PE2007001239 A PE 2007001239A PE 20081374 A1 PE20081374 A1 PE 20081374A1
Authority
PE
Peru
Prior art keywords
penten
amine
antipsychotic agent
isopropoxipyridin
methyl
Prior art date
Application number
PE2007001239A
Other languages
English (en)
Inventor
Scott R Breining
Sharon R Letchworth
Craig H Miller
James K Wamsley
Yun-De Xiao
John L Eveden
Edwin Jonson
Ladislay Mrzljak
Dan Widzowski
Kristen G Jordan
Original Assignee
Astrazeneca Ab
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39184604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081374(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Targacept Inc filed Critical Astrazeneca Ab
Publication of PE20081374A1 publication Critical patent/PE20081374A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMBINACION QUE COMPRENDE a) UN AGENTE ANTIPSICOTICO TAL COMO QUETIAPINA, EN UNA DOSIS ENTRE 5 Y 50 MG/KG Y b) UN AGONISTA DEL RECEPTOR NICOTINICO ALFA4/BETA2-NEURONAL TAL COMO (2S)-(4E)-N-METIL-5-[3-(5-ISOPROPOXIPIRIDIN)IL]-4-PENTEN-2-AMINA EN UNA DOSIS ENTRE 0,001 Y 0,05 MG/KG. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS Y UN KIT QUE COMPRENDE DICHA COMBINACION. DICHOS COMPUESTOS PRESENTAN UN EFECTO TERAPEUTICO SINERGICO, POR LO QUE SON UTILES EN EL TRATAMIENTO Y PREVENCION DE LA PROGRESION DE CONDICIONES PSICOTICAS Y/O EL DETERIORO DE LA FUNCION COGNITIVA EN CONDICIONES PSICOTICAS
PE2007001239A 2006-09-15 2007-09-14 Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina PE20081374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84475906P 2006-09-15 2006-09-15

Publications (1)

Publication Number Publication Date
PE20081374A1 true PE20081374A1 (es) 2008-10-30

Family

ID=39184604

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001239A PE20081374A1 (es) 2006-09-15 2007-09-14 Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina

Country Status (6)

Country Link
US (1) US20080085888A1 (es)
AR (1) AR062860A1 (es)
CL (1) CL2007002684A1 (es)
PE (1) PE20081374A1 (es)
TW (1) TW200829244A (es)
WO (1) WO2008034041A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790757B2 (en) 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2021325A2 (en) 2006-05-09 2009-02-11 AstraZeneca AB Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
US20100028447A1 (en) * 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
JP2010535237A (ja) * 2007-07-31 2010-11-18 ターガセプト・インコーポレイテッド （２ｓ）−（４ｅ）−ｎ−メチル−５−（３−（５−イソプロポキシピリジン）イル）−４−ペンテン−２−アミンの経皮投与
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
US20110130428A1 (en) * 2008-06-11 2011-06-02 Astrazeneca Ab Sublingual Compositions Comprising (2S) - (4E) -N-Methyl-5- (3- (5-Isopropoxypyridin) YL)-4-Penten-2-Amine
WO2010080757A2 (en) * 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
US20100278944A1 (en) * 2009-05-04 2010-11-04 Naturex, S.A. Application of american ginseng to enhance neurocognitive function
US9956241B2 (en) 2009-05-04 2018-05-01 Naturex, S.A. Application of American Ginseng to enhance neurocognitive function
EP2445502B2 (en) 2009-06-25 2022-09-28 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
EP2445343B1 (en) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
WO2011084851A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Asenapine produrugs
WO2011084850A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Prodrugs for the treatment of schizophrenia and bipolar disease
WO2011084846A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Quaternary ammonium salt prodrugs
WO2011084849A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Diaryldiazepine prodrugs for the treatment of neurological and psychological disorders
SG185497A1 (en) 2010-05-20 2012-12-28 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines
US8592427B2 (en) 2010-06-24 2013-11-26 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
IL296695B2 (en) 2011-03-18 2024-11-01 Alkermes Pharma Ireland Ltd Pharmaceutical preparations containing sorbitan esters
EP2790734B1 (en) 2011-12-15 2019-02-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
CA2867123C (en) 2012-03-19 2021-02-16 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
NZ730571A (en) 2012-09-19 2018-12-21 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
MX376057B (es) 2014-03-20 2025-03-07 Alkermes Pharma Ireland Ltd Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion.
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192946A (en) * 1978-06-29 1980-03-11 Ciba-Geigy Corporation Process for producing 3-hydroxy-5-halopyridines
DE3148651A1 (de) * 1981-12-09 1983-07-21 Henkel Kgaa "haarfaerbemittel, enthaltend 5-halo-2,3-pyridindiole als kupplerkomponente"
US4582823A (en) * 1984-08-15 1986-04-15 Warner-Lambert Company Method for treating schizophrenia and medicaments therefor
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
US5212188A (en) * 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) * 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US20020052497A1 (en) * 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
WO1997040011A1 (en) * 1996-04-23 1997-10-30 R. J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5811442A (en) * 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6232316B1 (en) * 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US6337351B1 (en) * 1998-10-22 2002-01-08 Targacept, Inc. Pharmaceutical compositions and methods for use
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
US6506769B2 (en) * 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US6743812B1 (en) * 2000-07-14 2004-06-01 Targacept, Inc. Pharmaceutical compositions and methods for use
US6432954B1 (en) * 2000-07-14 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7459469B2 (en) * 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型

Also Published As

Publication number Publication date
TW200829244A (en) 2008-07-16
US20080085888A1 (en) 2008-04-10
CL2007002684A1 (es) 2008-06-27
WO2008034041A2 (en) 2008-03-20
AR062860A1 (es) 2008-12-10
WO2008034041A3 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
PE20081374A1 (es) Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
ECSP088239A (es) Composición de liberación de fármaco sostenida
PA8591701A1 (es) Derivados de pirrolopirimidina
PE20121442A1 (es) Derivados de oxindol sustituido y composiciones farmaceuticas que los comprenden
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
MA30765B1 (fr) Derives innovants du thiophene
ECSP088240A (es) Composición de trazodona para administración una vez por día
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
SV2009003281A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.0
GT200600028A (es) Compuestos y composiciones como inhibidores de proteina kinasa
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
CR8258A (es) Derivados de azepine como agentes farmaceuticos
PE20081506A1 (es) Formulaciones de ansamicina
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
UY27598A1 (es) Composiciones farmacéuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
GT200500098A (es) Nuevos compuestos
GT200600114A (es) Derivados de ciclopropanocarboxamida
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal